 | • レポートコード：MRC23Q35874 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、82ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥406,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥812,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の循環腫瘍DNA診断市場について調査・分析し、世界の循環腫瘍DNA診断市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（検査キット、試薬）、用途別セグメント分析（病院、診断研究所、研究所、学術研究機関）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Grail, Inc.、Guardant Health, Inc.、Biodesix, Inc.、Exosome Diagnostics、Freenome Inc.、LungLife AI, Inc.、Inivata Ltd.、Personal Genome Diagnostics, Inc.、CellMax Lifeなどが含まれています。世界の循環腫瘍DNA診断市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、循環腫瘍DNA診断市場規模を推定する際に考慮しました。本レポートは、循環腫瘍DNA診断の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、循環腫瘍DNA診断に関するビジネス上の意思決定に役立てることを目的としています。 ・循環腫瘍DNA診断市場の概要 - 循環腫瘍DNA診断のタイプ別セグメント - 世界の循環腫瘍DNA診断市場規模：タイプ別分析（検査キット、試薬） - 循環腫瘍DNA診断の用途別セグメント - 世界の循環腫瘍DNA診断市場規模：用途別分析（病院、診断研究所、研究所、学術研究機関） - 世界の循環腫瘍DNA診断市場規模予測（2018年-2029年） ・循環腫瘍DNA診断市場の成長トレンド - 循環腫瘍DNA診断の地域別市場規模（2018年-2029年） - 循環腫瘍DNA診断市場ダイナミクス - 循環腫瘍DNA診断の業界動向 - 循環腫瘍DNA診断市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：検査キット、試薬 - 世界の循環腫瘍DNA診断のタイプ別市場規模（2018年-2023年） - 世界の循環腫瘍DNA診断のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、診断研究所、研究所、学術研究機関 - 世界の循環腫瘍DNA診断の用途別市場規模（2018年-2023年） - 世界の循環腫瘍DNA診断の用途別市場規模（2024年-2029年） ・循環腫瘍DNA診断の地域別市場規模 - 北米の循環腫瘍DNA診断市場規模（2018年-2029年） - アメリカの循環腫瘍DNA診断市場規模（2018年-2029年） - ヨーロッパの循環腫瘍DNA診断市場規模（2018年-2029年） - アジア太平洋の循環腫瘍DNA診断市場規模（2018年-2029年） - 中国の循環腫瘍DNA診断市場規模（2018年-2029年） - 日本の循環腫瘍DNA診断市場規模（2018年-2029年） - 韓国の循環腫瘍DNA診断市場規模（2018年-2029年） - インドの循環腫瘍DNA診断市場規模（2018年-2029年） - オーストラリアの循環腫瘍DNA診断市場規模（2018年-2029年） - 中南米の循環腫瘍DNA診断市場規模（2018年-2029年） - 中東・アフリカの循環腫瘍DNA診断市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Grail, Inc.、Guardant Health, Inc.、Biodesix, Inc.、Exosome Diagnostics、Freenome Inc.、LungLife AI, Inc.、Inivata Ltd.、Personal Genome Diagnostics, Inc.、CellMax Life ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Circulating Tumor DNA Diagnostics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Circulating Tumor DNA Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Circulating Tumor DNA Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Circulating Tumor DNA Diagnostics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Circulating Tumor DNA Diagnostics include Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics, Freenome Inc., LungLife AI, Inc., Inivata Ltd., Personal Genome Diagnostics, Inc. and CellMax Life, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor DNA Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor DNA Diagnostics.
The Circulating Tumor DNA Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Circulating Tumor DNA Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor DNA Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life
Segment by Type
Test Kits
Reagents
Segment by Application
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor DNA Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor DNA Diagnostics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Test Kits
1.2.3 Reagents
1.3 Market by Application
1.3.1 Global Circulating Tumor DNA Diagnostics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Diagnostics Laboratories
1.3.4 Research Laboratories
1.3.5 Academic Research Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor DNA Diagnostics Market Perspective (2018-2029)
2.2 Circulating Tumor DNA Diagnostics Growth Trends by Region
2.2.1 Global Circulating Tumor DNA Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Circulating Tumor DNA Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Circulating Tumor DNA Diagnostics Forecasted Market Size by Region (2024-2029)
2.3 Circulating Tumor DNA Diagnostics Market Dynamics
2.3.1 Circulating Tumor DNA Diagnostics Industry Trends
2.3.2 Circulating Tumor DNA Diagnostics Market Drivers
2.3.3 Circulating Tumor DNA Diagnostics Market Challenges
2.3.4 Circulating Tumor DNA Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor DNA Diagnostics Players by Revenue
3.1.1 Global Top Circulating Tumor DNA Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Circulating Tumor DNA Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Circulating Tumor DNA Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor DNA Diagnostics Revenue
3.4 Global Circulating Tumor DNA Diagnostics Market Concentration Ratio
3.4.1 Global Circulating Tumor DNA Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor DNA Diagnostics Revenue in 2022
3.5 Circulating Tumor DNA Diagnostics Key Players Head office and Area Served
3.6 Key Players Circulating Tumor DNA Diagnostics Product Solution and Service
3.7 Date of Enter into Circulating Tumor DNA Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor DNA Diagnostics Breakdown Data by Type
4.1 Global Circulating Tumor DNA Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Type (2024-2029)
5 Circulating Tumor DNA Diagnostics Breakdown Data by Application
5.1 Global Circulating Tumor DNA Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Circulating Tumor DNA Diagnostics Market Size (2018-2029)
6.2 North America Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
6.4 North America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor DNA Diagnostics Market Size (2018-2029)
7.2 Europe Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
7.4 Europe Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size (2018-2029)
8.2 Asia-Pacific Circulating Tumor DNA Diagnostics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2018-2023)
8.4 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor DNA Diagnostics Market Size (2018-2029)
9.2 Latin America Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
9.4 Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size (2018-2029)
10.2 Middle East & Africa Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
10.4 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Grail, Inc.
11.1.1 Grail, Inc. Company Detail
11.1.2 Grail, Inc. Business Overview
11.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Introduction
11.1.4 Grail, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.1.5 Grail, Inc. Recent Development
11.2 Guardant Health, Inc.
11.2.1 Guardant Health, Inc. Company Detail
11.2.2 Guardant Health, Inc. Business Overview
11.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Introduction
11.2.4 Guardant Health, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.2.5 Guardant Health, Inc. Recent Development
11.3 Biodesix, Inc.
11.3.1 Biodesix, Inc. Company Detail
11.3.2 Biodesix, Inc. Business Overview
11.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Introduction
11.3.4 Biodesix, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.3.5 Biodesix, Inc. Recent Development
11.4 Exosome Diagnostics
11.4.1 Exosome Diagnostics Company Detail
11.4.2 Exosome Diagnostics Business Overview
11.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Introduction
11.4.4 Exosome Diagnostics Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.4.5 Exosome Diagnostics Recent Development
11.5 Freenome Inc.
11.5.1 Freenome Inc. Company Detail
11.5.2 Freenome Inc. Business Overview
11.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Introduction
11.5.4 Freenome Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.5.5 Freenome Inc. Recent Development
11.6 LungLife AI, Inc.
11.6.1 LungLife AI, Inc. Company Detail
11.6.2 LungLife AI, Inc. Business Overview
11.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Introduction
11.6.4 LungLife AI, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.6.5 LungLife AI, Inc. Recent Development
11.7 Inivata Ltd.
11.7.1 Inivata Ltd. Company Detail
11.7.2 Inivata Ltd. Business Overview
11.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Introduction
11.7.4 Inivata Ltd. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.7.5 Inivata Ltd. Recent Development
11.8 Personal Genome Diagnostics, Inc.
11.8.1 Personal Genome Diagnostics, Inc. Company Detail
11.8.2 Personal Genome Diagnostics, Inc. Business Overview
11.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Introduction
11.8.4 Personal Genome Diagnostics, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.8.5 Personal Genome Diagnostics, Inc. Recent Development
11.9 CellMax Life
11.9.1 CellMax Life Company Detail
11.9.2 CellMax Life Business Overview
11.9.3 CellMax Life Circulating Tumor DNA Diagnostics Introduction
11.9.4 CellMax Life Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.9.5 CellMax Life Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details